<乌鸦传媒>Personalized Cancer Vaccine Boosts Recurrence-Free Survival in Melanoma Clinical implications apply to virtually all solid tumors and possibly hematologic malignancies Apr 17, 2023
<乌鸦传媒>FDA OKs Another PD-1 Inhibitor for Merkel Cell Carcinoma Retifanlimab produced responses in 52% of patients with untreated unresectable disease Mar 22, 2023
<乌鸦传媒>Vitamin B3 Doesn't Cut Skin Cancer Risk After Organ Transplant Randomized study finds no benefit with 12 months of nicotinamide versus placebo Mar 01, 2023
<乌鸦传媒>Long-Term Data Reinforce Targeted Combo Versus Single Agent for Advanced Melanoma Encorafenib-binimetinib tops vemurafenib, but checkpoint inhibitors remain first-line choice Dec 19, 2022
<乌鸦传媒>Xeljanz Cancer Risks Detailed New paper provides full results from ORAL Surveillance trial Dec 07, 2022
<乌鸦传媒>Melanoma Resistant to Anti-PD-1 Responds to Tumor Infiltrating Lymphocytes Almost a third of patients had objective responses, which deepened over time, study showed Nov 16, 2022
<乌鸦传媒>Mixed Results With Fecal Transplant to Stimulate Cancer Immunotherapy Response Encouraging activity with antibiotic-free protocol but not with vancomycin preconditioning Nov 14, 2022
<乌鸦传媒>Terry Bradshaw's Merkel Cell Carcinoma After beating bladder cancer, the Hall of Fame quarterback was diagnosed with a rare skin tumor Nov 10, 2022
<乌鸦传媒>Immunotherapy First for BRAF Melanoma Edges Out Targeted Combination "Clinically meaningful" improvement in 2- and 3-year survival Sep 28, 2022
<乌鸦传媒>Neoadjuvant Anti-PD-1 Strategy Prevails Over Adjuvant in Resectable Melanoma Large increase in event-free survival with neoadjuvant plus adjuvant versus only adjuvant therapy Sep 13, 2022
<乌鸦传媒>Neoadjuvant Cemiplimab Active in Resectable Cutaneous Squamous Cell Carcinoma Pathologic complete responses seen in 63% of patients in phase II data Sep 12, 2022
<乌鸦传媒>Tumor Infiltrating Lymphocytes Reemerge as Potential Melanoma Option More than 50% increase in 6-month PFS versus ipilimumab after progression on first-line anti-PD-1 Sep 12, 2022
<乌鸦传媒>Keytruda Plus T-VEC Falls Short in Unresectable Melanoma No significant survival benefit with combination, but certain patients lived longer Sep 02, 2022
<乌鸦传媒>Are Skin Lesion Analyzers Ready for Prime Time? FDA panel not fully on board to reclassify computer-aided melanoma detection devices Jul 30, 2022
<乌鸦传媒>TKI Plus Immunotherapy Active in Melanoma After Anti-PD-1 Progression More than a fifth of patients responded to lenvatinib-pembrolizumab combination Jul 26, 2022
<乌鸦传媒>Something Fishy About Tuna and Melanoma Risk Higher total fish intake linked with 22% higher risk of malignant tumors Jun 09, 2022
<乌鸦传媒>Stop Calling It Cancer; AI Gets a Win in Bladder Cancer; Lack of Price Transparency News, features, and commentary about cancer-related issues Apr 22, 2022
<乌鸦传媒>Intratumoral Combo Shrinks Melanomas Refractory to Anti-PD-1 But response rate driven primarily by injected lesions, expert points out Apr 14, 2022
<乌鸦传媒>Dual Immunotherapy Improves PFS in Melanoma Resistant to Anti-PD-1 Six-month PFS rate more than doubled with nivolumab/ipilimumab versus ipilimumab alone Apr 13, 2022
<乌鸦传媒>Novel Fixed-Dose Immunotherapy Combo Wins FDA Approval Nivolumab plus relatlimab doubled progression-free survival in unresectable melanoma Mar 21, 2022
<乌鸦传媒>Mixed Message for Ultrasound in High-Risk Cutaneous Head and Neck Cancer Nodal metastasis detected more often than by clinical exam, worrisome false-positive rate Mar 18, 2022
<乌鸦传媒>Novel Therapies Active in Head and Neck Cancers High response rate with oncolytic virus plus immunotherapy in cutaneous lesions Feb 28, 2022
<乌鸦传媒>Merkel Cell Carcinoma Much More Likely to Recur vs Other Skin Cancers 5-year recurrence rate was 40% compared with 19% for melanoma Feb 23, 2022
<乌鸦传媒>Active Surveillance for Melanoma Meets Reality of Loss to Follow-Up More than a third of patients lost to follow-up in "real-world" experience Jan 10, 2022
<乌鸦传媒>Melanoma Patient on Immunotherapy Develops Severe Dermatitis Clinicians faced with presumed dermatologic AEs urged to consider all differentials Jan 10, 2022
<乌鸦传媒>Long-Term Data Reinforce Standard of Care in Unresectable Melanoma Landmark trial shows median OS of 72.1 months with nivolumab-ipilimumab Dec 01, 2021
<乌鸦传媒>Case: VEGFR Inhibition in Merkel Cell Carcinoma Patient Disease stabilized after post-chemotherapy progression of the aggressive neuroendocrine cancer Oct 11, 2021
<乌鸦传媒>FDA Issues Orders Clarifying Rules for Marketing Sunscreens But more studies on sunscreen chemicals are still needed, advocacy group says Sep 24, 2021
<乌鸦传媒>In RA, Little Risk for Recurrent Cancer With Biologic Treatment Results important because most trials excluded patients with previous cancer, researchers note Sep 23, 2021
<乌鸦传媒>Adjuvant Pembrolizumab Boosts Recurrence-Free Survival in High-Risk Melanoma Also, fewer cases of distant recurrences in KEYNOTE-716 trial Sep 19, 2021
<乌鸦传媒>9/11 Responders Face Higher Risk of Multiple Cancers Longer follow-up sheds light on the long-term consequences of exposure to disaster site Sep 10, 2021
<乌鸦传媒>What's Causing Cancer Patient's Joint Pain While on Checkpoint Inhibitor? Here is how clinicians diagnosed this rare inflammatory side effect Aug 30, 2021
<乌鸦传媒>COVID Surges Emerge; FDA Warns About Chantix; Lions, Tigers, Bears Get Vaxxed A daily roundup of news on COVID-19 and the rest of medicine Jul 06, 2021
<乌鸦传媒>Start Thinking 'Cure'; One More Hug; Mortgages and Breast Cancer Survival News, features, and commentary about cancer-related issues Jun 16, 2021
<乌鸦传媒>Adjuvant Anti-PD-1 Misses on OS in High-Risk Melanoma But pembrolizumab topped active controls for relapse-free survival Jun 07, 2021
<乌鸦传媒>Lymph Node Findings on PET: Cancer or COVID Vaccine? Post-jab radiotracer uptake "could prompt unnecessary biopsies and treatments" May 26, 2021
<乌鸦传媒>Bad Day Sunshine: Benzene Found in Many Sun Care Products Valisure also detected the carcinogen in hand sanitizers earlier this year May 26, 2021
<乌鸦传媒>Novel Immunotherapy Boosts Melanoma Outcomes Adding LAG-3 checkpoint inhibitor to nivolumab extended PFS in patients with advanced disease May 19, 2021
<乌鸦传媒>Doubling Down on Immunotherapy in Advanced Melanoma Checkpoint inhibitor combo active after upfront anti-PD-1/L1 therapy May 09, 2021
<乌鸦传媒>Op-Ed: Dermatology Needs Lower Costs and Better Care A proposal for value-based care Apr 21, 2021
